GLP1R and liver cancer: Findings were consistent across sensitivity analyses.<h4>Conclusion</h4>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously.